Trial Profile
An expanded access program of enzalutamide after failure of docetaxel and abiraterone in patients with metastatic castrate resistant prostate cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Expanded access; Therapeutic Use
- 11 Dec 2015 New trial record